Kiniksa Pharmaceuticals International plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa Pharmaceuticals International plc is based in LONDON.
| Revenue (Most Recent Fiscal Year) | $423.24M |
| Net Income (Most Recent Fiscal Year) | $-43.19M |
| PE Ratio (Current Year Earnings Estimate) | 37.96 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.26 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1.31% |
| Net Margin (Trailing 12 Months) | -3.52% |
| Return on Equity (Trailing 12 Months) | -3.83% |
| Return on Assets (Trailing 12 Months) | -2.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.66 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.44 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.25 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 72.97M |
| Free Float | 33.95M |
| Market Capitalization | $2.05B |
| Average Volume (Last 20 Days) | 0.98M |
| Beta (Past 60 Months) | 0.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 53.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 53.95% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |